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Ankyrin defects are the most common cause of hereditary spherocytosis (HS). In some HS patients,
mutations in the ankyrin promoter have been hypothesized to lead to decreased ankyrin mRNA synthesis.
The ankyrin erythroid promoter is a member of the most common class of mammalian promoters which
lack conserved TATA, initiator or other promoter cis elements and have high G1C content, functional Sp1
binding sites and multiple transcription initiation sites. We identified a novel ankyrin gene promoter
mutation, a TG deletion adjacent to a transcription initiation site, in a patient with ankyrin-linked HS and ana-
lyzed its effects on ankyrin expression. In vitro, the mutant promoter directed decreased levels of gene
expression, altered transcription initiation site utilization and exhibited defective binding of TATA-binding
protein (TBP) and TFIID complex formation. In a transgenic mouse model, the mutant ankyrin promoter led
to abnormalities in gene expression, including decreased expression of a reporter gene and altered transcrip-
tion initiation site utilization. These data indicate that the mutation alters ankyrin gene transcription and
contributes to the HS phenotype by decreasing ankyrin gene synthesis via disruption of TFIID complex inter-
actions with the ankyrin core promoter. These studies support the model that in promoters that lack con-
served cis elements, the TFIID complex directs preinitiation complex formation at specific sites in core
promoter DNA and provide the first evidence that disruption of TBP binding and TFIID complex formation
in this type of promoter leads to alterations in start site utilization, decreased gene expression and a disease
phenotype in vivo.
INTRODUCTION
Hereditary spherocytosis (HS) is a common inherited hemoly-
tic anemia that affects all ethnic groups. The primary cellular
abnormality in HS is loss of erythrocyte membrane surface
area relative to intracellular volume, leading to spherical
shaped erythrocytes with decreased deformability. Defects of
the erythrocyte membrane protein ankyrin (ankyrin-1,
ANK1, OMIM 182900) are the most common cause of
HS (1–4). In some ankyrin-deficient HS patients, sequence
variations in the ankyrin core promoter region have been
hypothesized to lead to decreased ankyrin mRNA synthesis
(1,5,6). It is not known whether these are disease-causing
mutations or merely polymorphisms.
Significant progress has been made in our understanding of
core promoter structure and function. Core promoters have
been best studied in model organisms, particularly Drosophila,
which usually contain combinations of conserved cis elements
including a TATA box, a transcription factor IIB recognition
element, an initiator element (InR), a downstream promoter
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element (DPE) or the motif ten element (7–16). Mammalian
core promoters are more complex and may contain a TATA
box alone, a TATA box and an InR, an InR and a DPE etc.
or contain none of these conserved cis elements (8,17).
The ankyrin erythroid promoter is a member of the most
common class of mammalian promoters (.50%) (18) which
lack conserved cis elements and have high CþG content,
functional upstream Sp1 binding sites and multiple transcrip-
tion initiation sites. In this type of promoter, Sp1 activation
directs the general transcription machinery to form preinitia-
tion complexes in a region 40–100 bp downstream of its
binding sites (19,20). In the downstream region, it has been
hypothesized that the TATA-binding protein (TBP) of the
TFIID complex directs preinitiation complex formation at
the sequences in the promoter DNA that most closely
resemble TATA or InR elements (17). Disease-associated
mutations in mammalian promoters lacking conserved cis
elements have not been well characterized. Mutation of
known DNA-transcription factor binding sites or conserved
core promoter cis sequences provides understandable causes
for alterations in gene expression, but in most cases, the func-
tional significance of sequence variations in the promoter
region is unknown (21–26).
We have identified a novel erythroid ankyrin gene core
promoter mutation, a TG deletion dinucleotide at position
272/273 adjacent to a transcription initiation site, in a
patient with ankyrin-linked HS. In vitro and in vivo studies
demonstrated that the mutant promoter directed decreased
gene expression and led to alterations in transcription
initiation site utilization. The mutant ankyrin promoter also
demonstrated defective TBP binding and TFIID complex
formation. We conclude that the 272/273 mutation alters
ankyrin gene transcription and contributes to the HS pheno-
type by decreasing ankyrin synthesis via disruption of TFIID
complex interactions with the ankyrin core promoter. These
studies support the model that in promoters lacking conserved
cis elements, the TFIID complex directs preinitiation complex
formation at sites in core mammalian promoter DNA that
functionally resemble TATA or InR elements (17). Similar
sequence variants identified in other genes with this type of pro-
moter have been associated with a disease phenotype, suggesting
that disruption of TFIID complex formation in this type of
promoter is an under-recognized cause of genetic disease.
RESULTS
Qualitative and quantitative analyses of erythrocyte
membrane proteins
One-dimensional SDS–PAGE analyses of erythrocyte
membranes from the proband and her mother were qualitat-
ively normal, and no abnormal isoforms of any major mem-
brane proteins were observed (data not shown). Quantitative
analyses of spectrin and ankyrin content, as measured by the
ratios of spectrin/band 3 and ankyrin/band 3, respectively,
are shown in Table 1. The erythrocyte membranes of mother
demonstrate combined ankyrin and spectrin deficiency at a
level typical for other cases of ankyrin-linked, mild-to-moderate
HS, 70–90% (1). Combined ankyrin–spectrin deficiency
is a common finding in ankyrin-deficient erythrocytes, as
decreased or defective ankyrin membrane assembly may
lead to decreased availability of spectrin-binding sites on
ankyrin (2,27). Splenectomy is curative in most patients,
even those with severe HS and membrane protein deficiency,
as splenic sequestration of abnormal erythrocytes is the
primary determinant of erythrocyte survival in HS patients
(2,3). As is typical postsplenectomy, the membranes of
proband exhibited only mild-to-moderate ankyrin deficiency
because splenectomy reduces hemolysis, prolongs erythrocyte
life span, decreases the reticulocyte count and normalizes
erythrocyte membrane protein quantitation (27). In addition,
her membranes demonstrated a decreased ratio of protein
4.1a to protein 4.1b, indicating a young population of erythro-
cytes consistent with her postsplenectomy compensated
hemolysis. Prior to splenectomy, the proband suffered from
moderate to severe hemolytic anemia, Hb 8–10 g/dl, with
reticulocytosis and hyperbilirubinemia. This necessitated
splenectomy in childhood. The parents both suffered from
mild HS with compensated hemolysis. Neither parent required
splenectomy.
SSCP analyses and nucleotide sequencing
Screening of the coding region exons of the ankyrin gene pre-
viously identified a 20 bp deletion in exon 6 of one allele from
the proband (1). This deletion leads to frameshift and prema-
ture chain termination, creating effectively a null allele. The
deletion was confirmed by single-stranded conformational
polymorphism (SSCP) analyses and nucleotide sequencing
of exon 6 amplification products from the proband. The del-
etion was not observed in exon 6 amplification products
from her mother (data not shown). The father is presumed to
have the 20 bp exon 6 deletion as the cause of his HS pheno-
type. However, he is deceased and genetic material to confirm
this is not available.
To search for additional HS mutations, the ankyrin gene
promoter region was screened by SSCP of amplified
genomic DNA from the proband and her ankyrin-deficient
mother. An abnormal SSCP pattern was identified in the pro-
moter region in two separate PCR/SSCP reactions in the
proband and her mother (data not shown). Analysis of
the corresponding DNA sequence revealed a TG dinucleotide
deletion at position 272/273 relative to the ATG initiation
codon (Fig. 1). The DNA sequence at and around 272/273
does not contain consensus sequences for known DNA
binding proteins, but 272/273 is adjacent to one of the
ankyrin transcription initiation sites.
Transfection assays
Plasmids containing wild-type or mutant 272/273 ankyrin
promoter fragments linked to a firefly luciferase reporter
gene were transiently transfected into HeLa and K562 cells.
The relative luciferase activity was determined 24 h after
transfection and compared to the activity obtained with a
promoterless-luciferase negative control and a SV40 early
promoter-luciferase positive control. The 272/273 mutant
ankyrin promoter directed statistically lower levels of
luciferase reporter gene expression than the wild-type promo-
ter in both cell types (Table 2).
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In vitro transcription assays
In a cell-free in vitro transcription system using a run-off
technique, transcription from wild-type and mutant promoter
templates was analyzed with K562 cell nuclear extracts.
When analyzed in a quantitative slot blot assay, total transcrip-
tion products generated by the mutant promoter were
decreased to 53.2+ 7.6% (n ¼ 3, P ¼ 0.012) in K562 cell
extracts when compared with wild-type (Fig. 2, A).
Run-off products generated with HeLa cell extracts were
analyzed by acrylamide gel electrophoresis. HeLa cells are
enriched in basal transcription factors and are considered by
many to be the model system of choice for detailed study of
mammalian core promoters. The wild-type promoter template
generated bands corresponding to six transcription initiation
sites, identical to that seen in human erythroid cells (18).
In run-off transcription products generated by the mutant
272/273 promoter, the band corresponding to initiation site
4, immediately adjacent to the TG deletion, was not observed
(Fig. 2, B), and the intensity of the upstream start sites, par-
ticularly site 1, was increased.
Transgenic mice with human ankyrin promoter/Ag-globin
reporter genes
We have previously demonstrated that ankyrin promoter
mutations can lead to defects in expression of a linked
g-globin reporter gene in transgenic mice (28). We utilized
this model system to study the 272/273 ankyrin promoter
mutation. Wild-type or 272/273 mutant ankyrin promoter
fragments were fused to the human Ag-globin sequence
immediately upstream of the ATG initiation codon. Sixteen
wild-type and eight 272/273 mutant transgenic mouse lines
were analyzed. Southern blot analysis determined that the
transgene copy number in these mice ranged between 1 and
15 (Table 3).
RNase protection analysis of ankyrin/Ag-globin transgene
and endogenous murine a-globin gene expression was per-
formed with reticulocyte RNA using a riboprobe that contains
human Ag-globin and murine a-globin gene sequences on the
same transcript, allowing direct comparison of human
Ag-globin and murine a-globin mRNA levels. All 16 lines
with the wild-type ankyrin promoter expressed the Ag-globin
transgene (Table 4), and there was a significant correlation
with copy number (r2 ¼ 0.59, P , 0.001; Fig. 3, top, and
Table 4) (29). Ag-globin mRNA levels were significantly
decreased in transgenic mice with the 272/273 mutant
ankryin promoter when compared with transgenic mice with
the wild-type ankyrin promoter (P , 0.02) (Fig. 3, bottom,
and Table 4). Similar to wild-type promoter mice, Ag-globin
mRNA levels from mutant 272/273 promoter mice corre-
lated with copy number (r2 ¼ 0.846, P , 0.002). We have
previously shown that transgenic mice with the wild-type
ankyrin promoter express human Ag-globin in a uniform
pattern, i.e. in 100% of erythrocytes (28). We have also
shown that other sequence variants in the ankyrin promoter
region, 2108 T–C and 2153 G–A, lead to non-uniform,
varigated expression in transgenic mice (28). Therefore, we
analyzed the expression pattern of human Ag-globin protein
in the red cells of mutant 272/273 transgenic mice. Similar
Figure 1. Nucleotide sequence of subcloned PCR products corresponding to
the ankyrin promoter from the proband. Sequence of the wild-type allele.
The TG dinucleotide deleted in the mutant is boxed (top). Sequence of the
mutant allele with the TG deletion at 272/273 (bottom).
Table 1. Clinical, biochemical and molecular studies
Hb (g/dl) Reticulocyte
count (%)
Osmotic fragility Splenectomy (% of normal) Mutation
Ankyrin Spectrin
I-1 (mother) 13.5 8 Abnl No 83.3 82.5 Promoter 272/273 TG
I-2 (father) 17.0 8 Abnl No Unknowna Unknowna
II-1 (proband) 12.3 14 Abnl Yes 89b 103 1: Exon 6, 20 bp deletion;
2: Promoter, 272/273 TG
aThe father is deceased and genetic material is not available.
bValues are postsplenectomy.
Table 2. Transient transfection analyses
Promoter/reporter Cell type
K562 HeLa
Wild-type ankyrin promoter/luciferase 45.5+ 7.2 21.3+ 1.7
Mutant 272/273 ankyrin promoter/luciferase 38.0+ 6.0a 9.4+ 0.6b
SV40 promoter/luciferase 59.2+ 3.3 74.6+ 0.7
Promoterless/luciferase 1 1
Data presented are mean+ SD.
an ¼ 12, P, 0.05.
bn ¼ 9, P, 0.0005, both Student’s t-test.
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to wild-type, the mutant promoter expressing transgenic lines
demonstrated a uniform pattern of Ag-globin protein expression
(Table 4). We conclude that the mutations at 2108 and 2153
are distinct from the effects of the 272/273 mutation.
We analyzed Ag-globin mRNA expression in reticulocyte
RNA to determine whether transcription was properly initiated
in transgenic mice with the mutant ankyrin promoter. Hybri-
dization of a wild-type riboprobe to RNA from wild-type
promoter transgenic mice (Fig. 4, left, WT) revealed four
RNA transcription start sites corresponding to sites 1, 2, 3
and 4, previously identified in erythroid cell RNA (18) and
in our in vitro transcription studies. The two smallest bands,
corresponding to sites 5 and 6, were not found in either
wild-type or mutant 272/273 transgenic mice. After hybri-
dization of the labeled wild-type riboprobe to RNA from
mutant 272/273 transgenic mice, RNase digestion at the
site of the dinucleotide deletion produced only a single pro-
tected fragment truncated at position 272, demonstrating
the presence of the 272/273 mutation in these animals
(Fig. 4, left, 272/273).
To map the transcription initiation sites in 272/273 pro-
moter transgenic mice, a mutant 272/273 ankyrin promoter
riboprobe was used. When this probe was hybridized to
RNA from wild-type promoter transgenic mice, four protected
fragments were generated. These fragments were identical in
their frequency to those protected by the wild-type probe,
but were two nucleotides smaller (Fig. 4, right). When this
riboprobe was hybridized to RNA from transgenic mice
expressing the 272/273 promoter transgene, the band corre-
sponding to RNA initiation at site 4 was not observed, the rela-
tive amount of RNA initiated at site 3 was significantly
decreased (wild-type 48+ 0.2%, n¼ 3 versus mutant
23.7+ 1%, n ¼ 5, P , 0.001) and the relative amounts of
RNA initiated at site 1 (wild-type 16+ 2% versus mutant
40.1+ 1%, P , 0.001) and site 2 (20.6+ 4% versus
36.3+ 1%, P , 0.02) were significantly increased (Fig. 4,
left). The absence of site 4 and increased usage of upstream
sites 1 and 2 are consistent with the results from in vitro tran-
scription studies. We conclude that the 272/273 deletion
alters both the number of transcription initiation sites and
the frequency with which they are used in transgenic mice.
In vitro analyses of DNA–protein interactions
Oligonucleotide probes (Table 2) corresponding to the wild-
type and mutant ankyrin promoter sequences were analyzed
in standard acrylamide gel electrophoretic mobility shift
analyses (EMSAs) with K562 cell nuclear extracts. The
wild-type probe formed a slow migrating, very high molecular
weight complex not seen when using the mutant 272/273
probe (data not shown). The composition of this high molecu-
lar weight complex was unknown, but we hypothesized that it
involved a TFIID-containing complex because 272/273 is
immediately adjacent to a transcription initiation site and, in
core promoters lacking conserved cis elements like the
ankyrin promoter, Sp1 directs preinitiation complex formation
downstream of its binding sites (7), likely via TFIID com-
plexes directing preinitiation complex formation at sites in
the DNA that resemble TATA or InR elements (7).
To study TFIID complex formation, we utilized the well-
characterized magnesium agarose gel EMSA system with
combinations of recombinant TFIIA, TFIIB and TBP to
study ankyrin promoter–TFIID complex formation. This
system specifically overcomes the limitations of standard
acrylamide EMSA conditions used in our initial studies,
such as poor mobility of TFIID complexes in acrylamide
gels and epitope inaccessibility preventing detailed analyses
in competition and super-shift assays. Wild-type and mutant
272/272 32P-labeled ankyrin gene promoter fragments
from 2296 to 215 were used as probes. Complex formation
was most robust with the wild-type probe when a combination
of recombinant TFIIA and recombinant TBP were used. The
mutant probe exhibited reduced binding under the same con-
ditions, 39.9+ 4.7% (n ¼ 5, P ¼ 0.0002) of wild-type
control (Fig. 5A).
These data indicated that TFIID complexes are able to form
at the ankyrin promoter. To determine whether complexes
formed around the region of the 272/273 mutation, we
assessed binding of TBP, the protein of the TFIID complex
that contacts DNA, to the 272/273 promoter region by
in vitro DNase I footprinting. Wild-type and mutant ankyrin
promoter probes were incubated with recombinant TBP,
recombinant TBP plus recombinant TFIIA or HeLa cell
nuclear extracts. After digestion and gel electrophoresis, all
Figure 2. In vitro transcription. (A) A cell-free in vitro transcription system
using a run-off technique was used to analyze transcription from wild-type
and mutant promoter templates. In a quantitative slot blot assay with K562
cell extracts, transcription products generated by the mutant promoter were
decreased to 53.2+ 7.6% (P ¼ 0.012) compared with wild-type (B). Analysis
of run-off transcription products generated with HeLa cell extracts by gel
electrophoresis demonstrated that the transcription initiation site immediately
adjacent to the TG deletion, site 4, was absent in transcription products
generated by the mutant promoter when compared with the wild-type
promoter (right).
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three combinations of proteins demonstrated a protected
region from 268 to 275 with a wild-type ankyrin promoter
probe. Consistent with the magnesium agarose EMSA
results, this region was not protected when the mutant
272/273 ankyrin promoter probe was used (Fig. 5B).
DISCUSSION
Variability in the clinical severity in HS kindreds has been
well described, but no genetic mechanisms explaining this
Table 3. Expression of Ag-globin in transgenic mice
Transgenic line Transgene copy
number
g-globin mRNA/murine
a-globin mRNA
g-globin mRNA/murine
a-globin mRNA per copy
Percent g-globin protein
positive erythrocytes
Wild-type
A 1 0.020 0.02 100
B 1 0.023 0.023 ND
C 2 0.112 0.056 100
D 1 0.039 0.039 100
E 2 0.055 0.028 ND
F 15 0.400 0.027 ND
H 1 0.047 0.047 100
I 2 0.123 0.062 ND
J 3 0.169 0.056 100
K 6 0.281 0.047 ND
L 2 0.128 0.064 ND
M 3 0.129 0.043 ND
N 5 0.198 0.040 ND
O 4 0.244 0.061 ND
P 3 0.111 0.037 ND
Q 12 0.140 0.017 100
Correlation: r2 ¼ 0.59, P, 0.001 Mean+ SD: 0.044+ 0.014a
Mutant 272/273
A 11 0.479 0.044 100
B 1 0.026 0.026 ND
C 13 0.344 0.026 100
D 1 0.002b 0.002 ND
E 3 0.006b 0.002 ND
F 5 0.132 0.026 100
G 2 0.033 0.017 100
H 4 0.192 0.048 100
Correlation: r2 ¼ 0.846, P, 0.002 Mean+ SD: 0.024+ 0.016c
aP, 0.02 compared with 272/273.
bValues 0.008 and lower are indistinguishable from background.
cP, 0.02 compared with wild-type.
Table 4. Oligonucleotide primers
SSCP primers
Promoter A
Sense 50-CAGGGCCGAAGCTTCCTCTAC-30
Antisense 50-CGGGGAGAGCTGAGTTCAGAG-30
Promoter B
Sense 50-GCGACTAAACCGGACTCCCTTTC-30
Antisense 50-AGGAGGAGCAGCTGGGGC-30
Exon 6
Sense 50-GCTGGCGTCAGACGAGTCAGA-30
Antisense 50-AGCTCCTCCCTCCTCCTCGC-30
Electrophoretic mobility shift primers
Wild-type
Sense 50-GCAGAGGCTGCGGTGAGTCCGCCAGCC-30
Antisense 50-GGCTGGCGGACTCACCGCAGCCTCTGC-30
Mutant 272/2 73
Sense 50-GCAGAGGCTGCGGAGTCCGCCAGCC-30
Antisense 50-GGCTGGCGGACTCCGCAGCCTCTGC-30
Figure 3. Detection of ankyrin/32g-globin mRNA in reticulocytes of trans-
genic mice. An aliquot of 0.1 mg of RNA from adult reticulocytes was hybri-
dized to the 32P-labeled antisense riboprobe that protects exon 2 of the
ankyrin/Ag-globin transgene (top band) and exon 2 of the mouse a-globin
gene (lower band) and digested with RNase. (A) Wild-type ankyrin promoter
transgenic mice. (B) Mutant 272/273 ankyrin promoter transgenic mice. The
numbers above each lane indicate transgene copy number. Samples from indi-
vidual strains are shown from left to right in alphabetical order (Table 4).
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variability in ankyrin-linked HS have been described (30).
Variable penetrance, cis or trans ankyrin gene variants and
modifier genes have been hypothesized. In this German
kindred, the proband is a compound heterozygote for the
272/273 promoter mutation on one allele and the exon 6
frameshift mutation on the other allele. Both parents have
mild-to-moderate HS, i.e. with compensated hemolysis and
reticulocytosis, and like many HS patients, came to attention
only during family studies.
In most protein-encoding genes, initiation of RNA polymer-
ase II-dependent transcription requires assembly of numerous
proteins at the core promoter forming a preinitiation complex.
Recruitment of TFIID, a multiprotein complex, composed of the
TBP and associated proteins TAFs (TBP-associated factors), is
the first step in preinitiation complex formation (31–33). TFIID
recognizes and binds the core promoter through interactions of
TBP with the TATA box, the InR and/or the DPE (32,34–39).
In core promoters lacking conserved cis elements, Sp1 directs
formation of preinitiation complexes to a region 40–100 bp
downstream of its binding sites (7,20,34).
We have previously shown the functional importance of
two Sp1 sites positioned 80–100 bp upstream of the core
ankyrin promoter in directing gene expression (Fig. 6) (18).
Mutation or deletion of these Sp1 sites decreases or abolishes
promoter function. It has been hypothesized that in core promo-
ters lacking conserved cis elements, preinitiation complexes are
formed via binding of the TBP subunit of the TFIID complex to
promoter DNA sequences that most closely resemble func-
tional TATA-like or InR elements (20). If multiple sequences
are similarly desirable for recognition, multiple start sites will
result, as observed with the ankyrin promoter. In vitro studies
suggest that alterations within the start site region may lead
to relocalization of the start sites and variation in promoter
strength (40). It has been speculated that the variation in promo-
ter strength, as observed in this case, is due to alteration in
promoter context, an area of growing importance in promoter
function (15,34). There has been growing awareness of the
importance of promoter We observed alterations in start site
utilization and reporter gene expression in vitro and in vivo,
suggesting disruption of preinitiation complex formation by
the 272/273 mutation. As hypothesized (20), the wild-type
transcription initiation site interacted with the TFIID complex
in vitro and deletion of this site disrupted this interaction.
These studies indicate that the human wild-type ankyrin gene
erythroid promoter not only shares the structure of the class
of Drosophila core promoters lacking conserved cis elements
but also shares the functional characteristics including critical
upstream Sp1 sites. Our study is the first to demonstrate
altered gene expression and start site utilization causing a
disease phenotype by mutation in a core promoter lacking con-
served cis elements.
The lack of functional studies associated with sequence
variation in core promoters lacking conserved cis elements
precludes comment regarding the frequency of these
mutations. Similar to what we observed, a mutation in the ubi-
quitous promoter of the porphobilogen deaminase (HMBS)
gene (deletion of a nucleotide immediately 50 to one of the
transcription initiation sites), associated with the non-erythroid
form of acute intermittent porphyria, yielded results strikingly
similar to ours (41). The HMBS gene promoter is CþG rich,
lacks conserved cis elements and has multiple transcription
initiation sites. When compared with our acrylamide gel
EMSA, a wild-type HMBS probe yielded a very high molecu-
lar weight complex that was absent when a mutant probe was
used. Functional studies, including protein binding studies and
in vivo analyses of promoter function, were not performed. We
hypothesize that the HMBS mutation would also lead to
decreased gene expression and altered start site utilization.
We predict that variations in core promoter sequences are an
under-recognized cause of other inherited disorders also.
MATERIALS AND METHODS
Patients
The proband was from a German HS kindred. Diagnostic
criteria for HS were based on typical clinical features, the
Figure 5. In vitro analyses of DNA–protein interactions. (A) Probe binding
and complex formation in magnesium agarose gel electrophoresis. Wild-
type and mutant 272/272 32P-labeled ankyrin gene promoter fragments
from 2296 to 215 were used as probes in magnesium agarose gel electro-
phoresis assay. When compared with wild-type, the mutant probe exhibited
reduced binding with a combination of recombinant TFIIA and recombinant
TFIID under the same conditions, 39.9+ 4.7% (P ¼ 0.0002) of control. (B)
In vitro DNase I footprinting. In vitro DNase I footprinting was performed
with wild-type and mutant ankyrin core promoter probes and recombinant
TFIID (TBP) protein. A region from 268 to 275 was protected with a
wild-type promoter probe (left), which was not protected when a mutant
272/273 promoter probe (right) was used.
Figure 4. Transcription initiation site mapping in reticulocyte RNA from
transgenic mice. Wild-type riboprobe (left). Ribonuclease protection with
the wild-type riboprobe and RNA from 272/273 mutant promoter transgenic
mice identified a single, truncated protected fragment, demonstrating the pre-
sence of the deletion in these animals. Hybridization to RNA from wild-type
promoter transgenic mice identified four transcription initiation sites labeled
1–4. Each lane represents RNA from a separate transgenic line. Mutant
272/273 riboprobe (right). Ribonuclease protection with the mutant 272/
273 riboprobe and RNA from 272/273 mutant promoter transgenic mice
detected only three transcription initiation sites compared with four in the
wild-type promoter transgenic mice, with significant differences in relative
transcript expression.
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presence of spherocytes on peripheral blood smear, increased
incubated osmotic fragility and a negative direct antiglobulin
test. The proband has moderate HS and was splenectomized
in childhood. Postsplenectomy, the hemoglobin is 12.3 g/dl
and the reticulocyte count is 14.2%. Both parents have
normal hematocrits, increased reticulocyte counts and abnor-
mal erythrocyte incubated osmotic fragility, typical for the
diagnosis of HS with compensated hemolysis (Table 1).
Erythrocyte membrane preparation and quantitation
Erythrocyte membranes were prepared from whole blood as
described previously (42). Membrane proteins were separated
by SDS–PAGE in 4–16% gradient polyacrylamide gels and
stained with Coomassie blue. Ankyrin/band 3 and spectrin/
band 3 ratios were obtained by densitometric scanning of
the stained gels as described (42).
Mutation detection
Genomic DNA from the proband and mother was amplified by
PCR using two pairs of primers flanking the ankyrin gene ery-
throid promoter region and exon 6, respectively, as described
(Table 4) (1). The father is deceased and no genetic material
was available for study. SSCP analysis was performed accord-
ing to Eber et al. (1). SSCP was repeated on samples with
abnormal patterns on initial screening. Genomic DNA frag-
ments demonstrating a consistently abnormal SSCP pattern
were amplified in a second PCR reaction, subcloned and sub-
jected to nucleotide sequence analysis.
Transfection analyses
We have previously shown that a 286 bp minimal ankyrin
gene promoter fragment directs high-level expression of a luci-
ferase reporter gene in erythroid cells (18). A272/273 mutant
ankyrin promoter fragment corresponding to this 286 bp
promoter fragment generated by PCR amplification was sub-
cloned into the firefly luciferase reporter plasmid pGL2B
(Promega Corp., Madison, WI, USA) to yield p2962 72/273.
Test plasmids, p296 and p2962 72/273, were sequenced to
exclude cloning or PCR-generated artifacts. Transient transfec-
tion analyses were performed as described (18).
In vitro transcription
Cell-free in vitro transcription was performed using a run-off
technique (HeLaScribe, Promega, Madison, WI, USA) with
K562 or HeLa cell nuclear extracts as described (43). Tem-
plates for the reaction were the wild-type or the mutant
272/273 ankyrin core promoter fragments in pGL2B con-
taining both upstream Sp1 binding sites linearized with Sfu I
or a positive control template that contains the CMV immedi-
ate early promoter. For each reaction, 200 ng of template was
used. Final MgCl2 concentration in each reaction was 3 mM.
After incubation at 308C for 60 min, reactions were stopped
and ethanol precipitated. After adding loading dye, run-off
transcription products were analyzed by slot blot analysis or
on a denaturing polyacrylamide gel.
Preparation of mutant promoter–reporter constructs
for transgenic mice
To generate a mutant 272/273 ankyrin promoter/Ag-globin
transgene, a 276 bp Sma I/Bgl II fragment containing the
mutant ankyrin promoter (2291 to 220 plus polylinker
sequence) was excised from the pGL2B luciferase reporter
vector. A 1938 bp Bgl II/HindIII Ag-globin fragment was
excised from plasmid 72bspAg (29). A triple ligation consist-
ing of the ankyrin promoter, the Ag-globin gene and Sma I/
HindIII digested pSP72 was used to generate the mutant
272/273 ankyrin/Ag-globin plasmid. The ankyrin/Ag-globin
gene fragment (2244 bp) was excised from the plasmid with
EcoRV and HindIII and transgenic mice generated and ana-
lyzed as described (44).
Isolation of RNA and RNase protection assays (RPAs)
Total cellular RNA was extracted from adult reticulocytes,
obtained by collecting 200 ml of blood from phlebotomized
animals, as described (44). Three different riboprobes were
used for RPA. The first riboprobe contains sequences for
both exon 2 of the human Ag-globin gene and exon 2 of the
murine a-globin gene (28,45), ensuring that the human
Ag-globin and murine a-globin sequences are labeled to
equal specific activity, allowing direct comparison of human
Ag-globin and murine a-globin mRNA levels. To map the
transgene mRNA start sites, riboprobes were generated by
digesting either the wild-type or the 272/273 mutant
ankyrin promoter/Ag-globin transgenes described previously
with BstEII (located in exon 1 of the g-globin gene) and
HindIII (30 end of the transgene), blunting the ends and religat-
ing. The linear templates protect exon 1 of the g-globin
gene and extend through the ankyrin promoter region.
Fragments protected from RNase digestion were run in lanes
adjacent to a sequencing ladder generated from a wild-type
ankyrin promoter/Ag-globin transgene template with a
primer corresponding to the 30 end of g-globin exon 1 (50-
CCTTCCCAGGGTTTCTC-30). Probe preparation, hybridiz-
ation, RNA digestion and electrophoresis were carried out as
described (28,29). To quantitate the levels of mRNA or the
relative amounts of each transcript, the gel was exposed to a
phosphorimager screen and scanned on a molecular dynamics
phosphorimager.
Figure 6. The ankyrin gene erythroid promoter. The critical Sp1, Sp1/CACCC
and GATA-1 sites are shown. The previously identified transcription initiation
sites are denoted by the arrows. The location of the TG deletion is denoted by
the box.
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Electrophoretic mobility shift analyses (EMSA)
Nuclear extracts were prepared as described (46). Standard
acrylamide gel EMSAs were carried out as described using
oligonucleotide primers as probes (Table 2) (18). Magnesium
agarose EMSAs were performed exactly as described (47).
Wild-type or mutant 272/273 ankyrin probes excised from
pGL2B plasmids with Sma I and HindIII were end-labeled
with [g-32P]ATP. Labeled promoter fragments were incubated
with recombinant human TBP (Santa Cruz) alone or with
recombinant TFIIA (Austral Biologicals, San Ramon, CA,
USA) and/or recombinant TFIIB (Santa Cruz). In the
binding reactions, the amounts of recombinant proteins were
titrated over a range of concentrations (TBP and TFIIB both
66–660 ng and TFIIA 2–20 ng per reaction). The final KCl
concentration in each reaction mix was 60 mM. Reaction
products were electrophoresed at room temperature in 1.4%
magnesium agarose gels. The gels were dried and subjected
to autoradiography, followed by exposure to a phophorimager
screen and quantitative analyses on a molecular dynamics
phosphorimager.
In vitro DNase I footprinting
In vitro DNase I footprinting was performed as described (18)
with the same wild-type and mutant ankyrin promoter probes
used in the magnesium agarose EMSA as templates. Foot-
printing reaction mixes contained HeLa cell nuclear extracts,
recombinant TBP alone or a mixture of recombinant TBP
and recombinant TFIIA.
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